Ukraine may become European hub for clinical trials of original Western drugs

3 August 2021

Ukraine may become one of the European centers for clinical trials and studies of original Western drugs in years to come, according to recent statements by some leading local state officials and the Ukraine media reports.

According to recent statements made by Igor Kuzin, a chief sanitary doctor at Ukraine’s Health Ministry, which were made in an interview with the Ukrainian Apostrof magazine, in recent months five trials have already been completed by global drugmakers in Ukraine, while many more such trials will follow this year. Mr Kuzin added that one of such trials will be conducted by one of US majors in regard to its drug for prevention and treatment of COVID-19 patients.

According to some Ukrainian analysts and state officials, the sphere of clinical drugs is very well regulated and open in Ukraine, while is also due to the existence of the national register of clinical trials.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK